Compare NRIX & DFH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NRIX | DFH |
|---|---|---|
| Founded | 2009 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Homebuilding |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.7B |
| IPO Year | 2020 | 2021 |
| Metric | NRIX | DFH |
|---|---|---|
| Price | $19.18 | $19.87 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 13 | 1 |
| Target Price | ★ $26.77 | $26.00 |
| AVG Volume (30 Days) | ★ 1.9M | 342.9K |
| Earning Date | 01-27-2026 | 10-30-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 2.84 |
| Revenue | $83,687,000.00 | ★ $4,671,814,000.00 |
| Revenue This Year | $58.38 | N/A |
| Revenue Next Year | N/A | $1.86 |
| P/E Ratio | ★ N/A | $7.00 |
| Revenue Growth | ★ 48.32 | 15.98 |
| 52 Week Low | $8.18 | $17.61 |
| 52 Week High | $22.50 | $31.50 |
| Indicator | NRIX | DFH |
|---|---|---|
| Relative Strength Index (RSI) | 66.53 | 52.02 |
| Support Level | $19.02 | $17.75 |
| Resistance Level | $22.50 | $20.16 |
| Average True Range (ATR) | 1.18 | 0.72 |
| MACD | 0.10 | 0.23 |
| Stochastic Oscillator | 52.01 | 84.46 |
Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies.
Dream Finders Homes Inc is engaged in the home building business. The company's primary focus is on constructing and selling single-family homes across entry-level, first-time move-up, second-time move-up, and active adult markets. Its homebuilding operations are organized into four reportable segments: Southeast, Mid-Atlantic, Midwest, and Financial Services. It generates the majority of its revenue from the Midwest segment.